The use of medical identification jewellery in adults with adrenal insufficiency in Australia.

Abstract

Hydrocortisone stress dosing during illness can prevent adrenal crises (AC) in patients with adrenal insufficiency (AI). When patients cannot communicate, medical identification jewellery may facilitate parenteral hydrocortisone provision but patient adoption rates are not known. A cross-sectional analysis of Australian medical identification jewellery subscription data. Patients with AI aged 20years and over with an active subscription to a large medical jewellery provider. Subscription rates by AI subtype, geographic area, age and gender. There were 1955 patients with AI and an active subscription in the database, corresponding to a subscription rate of 105.79/million or approximately one-third of the AI population. The subscription rate was substantially higher in primary AI (60.72/million) than secondary AI (23.16/million), corresponding to approximately 60.7% and 11.6% of the estimated population prevalence of each disorder, respectively. There was substantial variation in use by state/territory, with the highest subscribing state having a rate of over four times that of the lowest (P<0.001). Women comprised 64.8% (n=1266) of the group. Subscription also varied by age, being highest in the 60-69year age group (165.15/million) and lowest in those aged 30-39years (47.23/million) (P<0.001). Few patients (4.8%, n=94) mentioned, either in their record or on their jewellery, the need for urgent parenteral hydrocortisone in the event of severe illness. Medical jewellery is a component of AC risk reduction. However, subscription appears to be underutilised in the Australian AI population, especially among patients with secondary AI. Urgent treatment recommendations should be inscribed on the jewellery.